Table 1.

Patient demographics and baseline characteristics

	Adalimumab 80 mg EOW (n = 28)
Males	16 (57.1)
Age, years	33.6±10.1
Weight, kg	55.35±11.6
BMI	20.27±4.3
Tobacco
Current user	2 (7.1)
Never used	25 (89.3)
Alcohol (nondrinker)	13 (46.4)
Duration of CD, years	8.61±6.3
CDAI	308.4±93.4
CRP, mg/dL	2.35 (0.25–6.78)
Prior infliximab use	19 (67.9)
Concomitant medication use at baseline
Aminosalicylates	23 (82.1)
Immunosuppressantsa	13 (46.4)
Antibioticsb	7 (25.0)
Corticosteroids	2 (7.1)

Values are n (%), mean ± SD, or median (range), as appropriate. BMI, body mass index; CD, Crohn disease; CDAI, Crohn disease activity index; CRP, C-reactive protein; EOW, every other week.

^aAzathioprine, mercaptopurine, tacrolimus.

^bCiprofloxacin, metronidazole.